BR9814220A - Formulações compreendendo paroxetinadissolvida - Google Patents

Formulações compreendendo paroxetinadissolvida

Info

Publication number
BR9814220A
BR9814220A BR9814220-8A BR9814220A BR9814220A BR 9814220 A BR9814220 A BR 9814220A BR 9814220 A BR9814220 A BR 9814220A BR 9814220 A BR9814220 A BR 9814220A
Authority
BR
Brazil
Prior art keywords
formulations
solid
paroxetine
solutions
forms
Prior art date
Application number
BR9814220-8A
Other languages
English (en)
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9814220A publication Critical patent/BR9814220A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMULAçõES COMPREENDENDO PAROXETINADISSOLVIDA". A presente invenção refere-se a formulaçõesfarmacêuticas em que a paroxetina está em solução em umveículo sólido, semi-sólido ou líquido. As soluções são usadas paraencher cápsulas, ou soluções sólidas de auto-suporte sãomoldadas em formas de dosagem sólidas tais como tabletes epelotas. Também são mostradas formulações liquidas em que umagente solubilizante é usado para solubilizar paroxetina em óleose/ou lipídios, e métodos para evitar que outras formas deparoxetina se convertam em hemi-hidrato de veículos ouexcipientes anidros ou hidrofóbicos.
BR9814220-8A 1997-11-21 1998-11-18 Formulações compreendendo paroxetinadissolvida BR9814220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation
PCT/GB1998/003471 WO1999026625A1 (en) 1997-11-21 1998-11-18 Formulations comprising dissolved paroxetine

Publications (1)

Publication Number Publication Date
BR9814220A true BR9814220A (pt) 2001-12-26

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814220-8A BR9814220A (pt) 1997-11-21 1998-11-18 Formulações compreendendo paroxetinadissolvida

Country Status (24)

Country Link
EP (1) EP1033986A1 (pt)
JP (1) JP2001523718A (pt)
KR (1) KR20010032320A (pt)
CN (1) CN1279608A (pt)
AP (1) AP2000001821A0 (pt)
AR (1) AR015485A1 (pt)
AU (1) AU1168099A (pt)
BG (1) BG104527A (pt)
BR (1) BR9814220A (pt)
CO (1) CO4970832A1 (pt)
DZ (1) DZ2658A1 (pt)
EA (1) EA200000552A1 (pt)
GB (1) GB9724544D0 (pt)
HU (1) HUP0100580A3 (pt)
IL (1) IL136106A0 (pt)
MA (1) MA24704A1 (pt)
NO (1) NO20002590L (pt)
OA (1) OA11385A (pt)
PE (1) PE20000381A1 (pt)
PL (1) PL340555A1 (pt)
SK (1) SK7342000A3 (pt)
TR (1) TR200001423T2 (pt)
WO (1) WO1999026625A1 (pt)
ZA (1) ZA9810637B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (en) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
WO2001002393A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
HUP0000960A3 (en) * 1997-01-15 2001-04-28 Smithkline Beecham Plc Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
BG104527A (en) 2001-04-30
AU1168099A (en) 1999-06-15
OA11385A (en) 2004-01-27
MA24704A1 (fr) 1999-07-01
ZA9810637B (en) 2000-05-22
DZ2658A1 (fr) 2003-03-22
EP1033986A1 (en) 2000-09-13
HUP0100580A2 (hu) 2002-04-29
NO20002590D0 (no) 2000-05-19
PL340555A1 (en) 2001-02-12
PE20000381A1 (es) 2000-05-07
NO20002590L (no) 2000-07-19
EA200000552A1 (ru) 2000-10-30
TR200001423T2 (tr) 2000-10-23
JP2001523718A (ja) 2001-11-27
SK7342000A3 (en) 2000-12-11
CN1279608A (zh) 2001-01-10
CO4970832A1 (es) 2000-11-07
IL136106A0 (en) 2001-05-20
WO1999026625A1 (en) 1999-06-03
HUP0100580A3 (en) 2002-05-28
GB9724544D0 (en) 1998-01-21
AR015485A1 (es) 2001-05-02
KR20010032320A (ko) 2001-04-16
AP2000001821A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
BR9814220A (pt) Formulações compreendendo paroxetinadissolvida
ES2187822T3 (es) Comprimidos de disgregacion rapida.
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
EP0221732A3 (en) Sustained release tablets
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BR9908488A (pt) Composição farmacêutica de topiramato
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
GR1002847B (el) Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
AR026197A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
BR0008713A (pt) Processos para preparar formulações ecomposições farmacêuticas orais com ecb
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
WO1998001124A3 (en) Pharmaceutical preparation containing nimesulide for topical use
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
BR9806303A (pt) Sistema de distrituição de droga termoformado, e, unidade de dosagem
AU739270B2 (en) Mucosal delivery system comprising lipophilic thrombin inhibitors
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
ID21266A (id) Senyawa tersubstitusi-sulfonamida, proses pembuatannya, penggunaannya sebagai obat atau diagnostik, dan obat yang mengandung senyawa tersebut
JPS5683418A (en) Fomentation

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]